SS-31 is a short peptide that targets mitochondria, the energy-producing structures inside your cells

SS-31 (also called Elamipretide) is a four-amino-acid peptide designed to enter mitochondria and protect them from damage. Unlike many compounds in the NAD pathway that work by boosting NAD levels themselves, SS-31 takes a different approach: it stabilizes the inner membrane of the mitochondrion, which can help preserve the cell's ability to produce energy even when that energy system is under stress.

The peptide was originally developed in Japan and has been studied in both animal and human research for more than a decade. It works by binding to cardiolipin, a fat molecule that sits in the mitochondrial membrane. This binding appears to reduce the leakage of electrons and the buildup of harmful reactive oxygen species—byproducts of energy production that can damage cells over time.

Because mitochondrial function declines with age and in certain diseases, SS-31 has drawn interest from researchers studying aging, heart disease, and neurodegenerative conditions. It is not yet approved by the FDA for general use, though clinical trials have been conducted in specific patient populations.

Key Takeaways

  • SS-31 is a peptide that protects mitochondrial membranes rather than directly raising NAD levels, making it a complementary approach within the NAD pathway category.
  • The peptide binds to cardiolipin in the mitochondrial inner membrane and may reduce oxidative stress and energy loss inside cells.
  • Research has focused on heart disease, muscle disorders, and age-related decline, though human studies remain limited outside of clinical trial settings.
  • SS-31 is not currently approved by the FDA for over-the-counter use, and availability outside of research studies is extremely limited.

How SS-31 differs from other NAD pathway compounds

Most compounds in the NAD pathway work by increasing NAD levels directly—either by providing precursors like NMN or NR, or by blocking enzymes that break NAD down. SS-31 does neither. Instead, it assumes that even if NAD levels are adequate, the mitochondrial machinery itself may be damaged or leaking energy, and it addresses that damage directly.

This makes SS-31 a potential partner to other NAD compounds rather than a replacement. A person interested in supporting mitochondrial health might theoretically use both an NAD booster and SS-31, since they work through different mechanisms. However, no large human studies have tested this combination, so the practical benefit of stacking them remains unknown.

What research has shown so far

Most of the evidence for SS-31 comes from laboratory and animal studies, which have shown that the peptide can reduce mitochondrial damage in heart cells, muscle cells, and neurons. In animal models of heart disease and muscular dystrophy, SS-31 has slowed disease progression and improved energy production in affected tissues.

Human research is much more limited. A small clinical trial in patients with a rare mitochondrial disease called Barth syndrome showed that SS-31 improved exercise capacity and heart function. Another trial in heart failure patients found improvements in cardiac output. These results are promising but involve small numbers of participants and specific disease populations, not healthy people seeking anti-aging benefits.

No large, long-term studies have tested SS-31 in healthy adults, so claims about its effects on aging, longevity, or general wellness remain speculative. The research that exists focuses on disease reversal or slowing, not on prevention in people without diagnosed conditions.

How SS-31 is administered and what we know about dosing

In clinical trials, SS-31 has been given as an intravenous infusion—a needle placed in a vein that delivers the peptide directly into the bloodstream. This route was chosen because peptides are broken down by stomach acid and digestive enzymes, so swallowing them does not work. The peptide is small enough to cross the blood-brain barrier and enter mitochondria in many tissues, but it still needs to reach the bloodstream first.

Dosing in human trials has varied depending on the condition being studied, but typical doses have ranged from 0.05 to 0.5 milligrams per kilogram of body weight, given as a single infusion or repeated doses over weeks. Outside of clinical trials, there is no established standard dose, and dosing information is not available because the compound is not marketed as a consumer product.

Some online vendors sell peptides they claim are SS-31, but these products are not regulated by the FDA, their purity and identity cannot be verified, and injecting unregulated peptides carries real risks including infection, allergic reaction, and unknown contaminants.

Potential side effects and safety considerations

In the clinical trials conducted so far, SS-31 has been generally well tolerated, with few serious adverse events reported. Some participants experienced mild injection-site reactions, headache, or nausea, but these were uncommon and usually resolved quickly. No major organ damage or long-term toxicity has been documented in the human studies published to date.

However, the total number of people who have received SS-31 in controlled settings remains small—likely in the hundreds rather than thousands. Long-term safety data in healthy people does not exist. Because the peptide works inside mitochondria and affects energy production at a fundamental level, there is a theoretical possibility of unintended effects in tissues that depend heavily on precise mitochondrial regulation, such as the heart or brain, but this has not been observed in available research.

Anyone considering SS-31 should be aware that products sold outside of clinical trials are unregulated and their contents cannot be verified. Injecting unknown substances carries infection risk and the possibility of allergic or toxic reactions.

Current availability and research status

SS-31 is not approved by the FDA for any indication and is not available through standard prescription channels. It exists primarily in research settings, where it is used in clinical trials for specific diseases. A few trials are ongoing in the United States and internationally, mostly focused on heart disease, mitochondrial disorders, and age-related muscle loss.

If you are interested in participating in a clinical trial, the website ClinicalTrials.gov allows you to search for active studies by condition and location. Trials involving SS-31 are rare, but new ones may be registered as research continues.

Outside of clinical trials, SS-31 is sometimes sold by peptide vendors online, but these products are not regulated, not approved for human use, and their quality cannot be assured. The FDA has issued warnings about unregulated peptide products, and purchasing them carries legal and health risks.

How SS-31 fits into a broader mitochondrial health strategy

If your interest in SS-31 stems from a desire to support mitochondrial function and energy production as you age, there are other approaches with more established evidence and greater accessibility. Regular aerobic exercise is one of the most powerful ways to improve mitochondrial number and function. Resistance training also stimulates mitochondrial adaptation. Both have been studied extensively in humans and require no pharmaceutical intervention.

Dietary approaches also matter: a diet rich in antioxidants (from vegetables, fruits, and nuts) and adequate in protein supports mitochondrial health. Some people also explore NAD boosters like NMN or NR, which have more human research behind them than SS-31 does, though they are also not FDA-approved for anti-aging use.

SS-31 may eventually play a role in treating specific mitochondrial diseases or age-related conditions, but that role will likely be defined through clinical research over the next several years. For now, it remains a research compound rather than a practical option for most people.

Frequently Asked Questions

Is SS-31 the same as Elamipretide?

Yes. Elamipretide is the pharmaceutical name for SS-31. The compound is sometimes referred to by either name in research literature and clinical trials. Elamipretide is the name used in formal drug development, while SS-31 is the original research designation.

Can I take SS-31 as a pill or injection at home?

SS-31 cannot be taken as a pill because peptides are destroyed by stomach acid. It must be injected intravenously (into a vein) to reach the bloodstream. Home injection of unregulated peptides carries serious risks including infection and unknown contaminants. It is only administered in clinical trial or medical settings where sterility and dosing can be controlled.

Will SS-31 slow aging or extend lifespan in humans?

There is no human evidence that SS-31 slows aging or extends lifespan. Animal studies suggest it may slow age-related decline in specific tissues, but these findings have not been tested in healthy humans. Any claims about anti-aging effects in people are speculative.

How does SS-31 compare to NAD boosters like NMN?

SS-31 and NAD boosters work differently. NAD boosters increase the raw material available for energy production, while SS-31 protects the mitochondrial structures that use that material. They target different parts of the same system, so theoretically they could complement each other, but no human studies have tested this combination.

What should I do if I am interested in mitochondrial health research?

You can search ClinicalTrials.gov for ongoing studies in your area. If you have a diagnosed mitochondrial disease or heart condition, ask your doctor whether any trials might be relevant to you. For general mitochondrial support, exercise and diet remain the most evidence-based approaches available today.